Literature DB >> 10884513

Pharmacological evaluation of aerosolized cannabinoids in mice.

A H Lichtman1, J Peart, J L Poklis, D T Bridgen, R K Razdan, D M Wilson, A Poklis, Y Meng, P R Byron, B R Martin.   

Abstract

The reemergence on the debate of the use of marijuana for medicinal purposes has been the impetus for developing an acceptable delivery form of aerosolized cannabinoids. The goals of the present study were to: (1) develop and characterize the physical properties of an aerosolized form of Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the major psychoactive constituent present in marijuana; and (2) assess the pharmacological effects of cannabinoid inhalation in mice. A Small Particle Aerosol Generator (SPAG) nebulizer, used to generate the aerosol, had an output of approximately 0.154 mg/l of aerosolized Delta(9)-THC with a 2.0 microm mass median aerodynamic diameter and a 2.2 geometric standard deviation (GSD). Virtually all the particles were less than 5.0 microm in diameter suggesting that they were sufficiently small to penetrate deeply into the lungs. Inhalation exposure to aerosolized Delta(9)-THC in mice elicited antinociceptive effects that were dependent on concentration and exposure time with an estimated Delta(9)-THC dose of 1.8 mg/kg. On the other hand, inhalation exposure to Delta(9)-THC failed to produce two other indices indicative of cannabinoid activity, hypothermia and decreases in spontaneous locomotor activity. The antinociceptive effects occurred within 5 min of exposure and lasted approximately 40 min in duration. The cannabinoid receptor antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR 141716A), but not naloxone, blocked these antinociceptive effects (AD(50)=0.09 mg/kg) indicating a cannabinoid receptor mechanism of action. Similarly, inhalation exposure to a water soluble cannabinoid analog, 3-(5'-cyano-1', 1'dimethylheptyl)-1-(4-N-morpholinobutyrloxy)-Delta(8)-te trahydrocann abinol (O-1057), produced antinociception that was blocked by SR 141716A. These results demonstrate that the development of an aerosolized form of cannabinoids for human medicinal use is feasible.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10884513     DOI: 10.1016/s0014-2999(00)00321-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  14 in total

1.  Selective breeding for high alcohol preference is associated with increased sensitivity to cannabinoid reward within the nucleus accumbens shell.

Authors:  Sheketha R Hauser; Simon N Katner; Robert A Waeiss; William A Truitt; Richard L Bell; William J McBride; Zachary A Rodd
Journal:  Pharmacol Biochem Behav       Date:  2020-07-23       Impact factor: 3.533

Review 2.  Modeling drug exposure in rodents using e-cigarettes and other electronic nicotine delivery systems.

Authors:  Cristina Miliano; E Reilly Scott; Laura B Murdaugh; Emma R Gnatowski; Christine L Faunce; Megan S Anderson; Malissa M Reyes; Ann M Gregus; Matthew W Buczynski
Journal:  J Neurosci Methods       Date:  2019-10-12       Impact factor: 2.390

Review 3.  Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol.

Authors:  Douglas L Boggs; Jacques D Nguyen; Daralyn Morgenson; Michael A Taffe; Mohini Ranganathan
Journal:  Neuropsychopharmacology       Date:  2017-09-06       Impact factor: 7.853

4.  Enhancing effects of acute exposure to cannabis smoke on working memory performance.

Authors:  Shelby L Blaes; Caitlin A Orsini; Hannah M Holik; Toneisha D Stubbs; Shandera N Ferguson; Sara C Heshmati; Matthew M Bruner; Shannon C Wall; Marcelo Febo; Adriaan W Bruijnzeel; Jennifer L Bizon; Barry Setlow
Journal:  Neurobiol Learn Mem       Date:  2018-12-03       Impact factor: 2.877

Review 5.  Therapeutic potential of cannabinoids in CNS disease.

Authors:  J Ludovic Croxford
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 6.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

7.  Self-administration of methamphetamine aerosol by male and female baboons.

Authors:  Richard W Foltin
Journal:  Pharmacol Biochem Behav       Date:  2018-03-13       Impact factor: 3.533

8.  Effects of Δ9-THC and cannabidiol vapor inhalation in male and female rats.

Authors:  Mehrak Javadi-Paydar; Jacques D Nguyen; Tony M Kerr; Yanabel Grant; Sophia A Vandewater; Maury Cole; Michael A Taffe
Journal:  Psychopharmacology (Berl)       Date:  2018-06-16       Impact factor: 4.530

9.  Inhaled delivery of Δ(9)-tetrahydrocannabinol (THC) to rats by e-cigarette vapor technology.

Authors:  Jacques D Nguyen; Shawn M Aarde; Sophia A Vandewater; Yanabel Grant; David G Stouffer; Loren H Parsons; Maury Cole; Michael A Taffe
Journal:  Neuropharmacology       Date:  2016-05-30       Impact factor: 5.250

Review 10.  Translational models of cannabinoid vapor exposure in laboratory animals.

Authors:  Catherine F Moore; Jeffrey W Stiltner; Catherine M Davis; Elise M Weerts
Journal:  Behav Pharmacol       Date:  2022-04-01       Impact factor: 2.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.